St. John's Wort increases expression of P-glycoprotein: Implications for drug interactions

British Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2002, Pages 75-82

  Feely, J ^a   Kavanagh, P ^a   Barry, M ^a   Spiers, J P ^a   Hennessy, M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Flow cytometry; P glycoprotein; Ritonavir; St John's Wort

Indexed keywords

GLYCOPROTEIN P; PROTEINASE INHIBITOR; RITONAVIR; CYTOCHROME P450 3A4; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PLACEBO; RHODAMINE 123; VIMENTIN;

ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERACTION; FEMALE; HERB DRUG INTERACTION; HUMAN; HYPERICUM; LYMPHOCYTE; MALE; METABOLISM; NONPARAMETRIC TEST; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; DENSITY GRADIENT CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG TRANSPORT; ENZYME INDUCTION; ENZYME SUBSTRATE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN CELL; NAUSEA; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; XEROSTOMIA;

ANALYSIS OF VARIANCE; DRUG INTERACTIONS; FEMALE; HERB-DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERICUM; LYMPHOCYTES; MALE; P-GLYCOPROTEIN; RITONAVIR; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 0036007742     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01516.x     Document Type: Article

References (48)

1. Indinavir concentrations and St John's Wort
2. Acute heart transplant rejection due to Saint John's Wort
3. St John's Wort: Hypericum perforatum
4. St John's Wort for depression: A systematic review
5. St John's Wort for depression: A meta-analysis of well defined clinical trials
6. Equivalence of St John's Wort extract (Ze 117) and fluoxetine: A randomised, controlled study in mild-moderate depression
7. St John's Wort for depression - An overview and meta-analysis of randomised clinical trials
8. Second thoughts about the safety of St John's Wort
9. Herb-drug interactions
10. Trends in alternative medicine use in the United States 1990-1997
11. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin
12. Pharmacokinetic interaction of digoxin with an herbal extract from St John's Wort (Hypericum perforatum)
13. Effect of St John's Wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers
14. St John's Wort: Effect on CYP3A4 activity
15. Inhibition of human cytochrome P450 enzymes by constituents of St John's Wort, an herbal preparation used in the treatment of depression
16. St John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor
17. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A4 induction
18. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
19. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter
20. Absence of the MDR1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
21. Biochemical, cellular and pharmacological aspects of the multidrug transporter
22. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins
23. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cydosporin A and its analogue, PSC833
24. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
25. Determination of Hypericin in plasma by high-performance liquid chromatography
26. High-performance liquid chromatographic determination of biologically active hypericin in vegetable extracts and alcoholic beverages
27. The HIV 1 protease as a therapeutic target for AIDS
28. Saquinavir pharmacokinetics alone and in combination with ritonavir in patients with HIV disease
29. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
30. A new PCR MIMIC strategy to quantify low MDR1 mRNA levels in drug resistant cell lines and AML blast samples
31. Ritonavir: Clinical pharmacokinetics and interactions with other HIV agents
32. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
33. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
34. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
35. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
36. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
37. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
38. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporin analog SDZ PSC 833
39. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin
40. Modulation of MDR1 and CYP3A expression by dexamehasone: Evidence for an inverse regulation in the adrenals
41. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway
42. SXR. A novel steroid and xenobiotic-sensing nuclear receptor
43. In the regulatory region of these genes the human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
44. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module
45. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin
46. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P x glycoprotein by oral treatment of mice with PSC833
47. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
48. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel